SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Samuelsson Martin)
 

Sökning: WFRF:(Samuelsson Martin) > (2010-2014) > Imbalanced Kynureni...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004191naa a2200445 4500
001oai:DiVA.org:liu-110785
003SwePub
008140922s2014 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:225288889
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1107852 URI
0247 a https://doi.org/10.4137/IJTR.S168002 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2252888892 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Kegel, Magdalena E.u Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden4 aut
2451 0a Imbalanced Kynurenine Pathway in Schizophrenia
264 1b Libertas Academica,c 2014
338 a electronic2 rdacarrier
520 a Several studies suggest a role for kynurenic acid (KYNA) in the pathophysiology of schizophrenia. It has been proposed that increased brain KYNA levels in schizophrenia result from a pathological shift in the kynurenine pathway toward enhanced KYNA formation, away from the other branch of the pathway leading to quinolinic acid (QUIN). Here we investigate the levels of QUIN in cerebrospinal fluid (CSF) of patients with schizophrenia and healthy controls, and relate those to CSF levels of KYNA and other kynurenine metabolites from the same individuals. CSF QUIN levels from stable outpatients treated with olanzapine (n = 22) and those of controls (n = 26) were analyzed using liquid chromatography-mass spectrometry. No difference in CSF QUIN levels between patients and controls was observed (20.6 ± 1.5 nM vs. 18.2 ± 1.1 nM, P = 0.36). CSF QUIN was positively correlated to CSF kynurenine and CSF KYNA in patients but not in controls. The CSF QUIN/KYNA ratio was lower in patients than in controls (P = 0.027). In summary, the present study offers support for an over-activated and imbalanced kynurenine pathway, favoring the production of KYNA over QUIN in patients with schizophrenia.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
7001 a Bhat, Mariau AstraZeneca, Research and Development, Innovative Medicines, Personalised Healthcare and Biomarkers, Translational Science Centre, Science for Life Laboratory, Solna, Sweden / Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Skogh, Elisabethu Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för neurovetenskap,Hälsouniversitetet,Psykiatriska kliniken4 aut0 (Swepub:liu)elisk66
7001 a Samuelsson, Martinu Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för neurovetenskap,Hälsouniversitetet,Psykiatriska kliniken4 aut0 (Swepub:liu)marsa78
7001 a Lundberg, Kristinau Linköpings universitet,Avdelningen för neurovetenskap,Hälsouniversitetet4 aut
7001 a Dahl, Marja-Liisau Karolinska Institutet4 aut
7001 a Sellgren, Carlu Karolinska Institutet4 aut
7001 a Schwieler, Lillyu Karolinska Institutet4 aut
7001 a Engberg, Göranu Karolinska Institutet4 aut
7001 a Schuppe-Koistinen, Inau Karolinska Institutet4 aut
7001 a Erhardt, Sophieu Karolinska Institutet4 aut
7102 a Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Swedenb AstraZeneca, Research and Development, Innovative Medicines, Personalised Healthcare and Biomarkers, Translational Science Centre, Science for Life Laboratory, Solna, Sweden / Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden4 org
7730 t International Journal of Tryptophan Researchd : Libertas Academicag 7, s. 15-22q 7<15-22x 1178-6469
8564 u https://liu.diva-portal.org/smash/get/diva2:748978/FULLTEXT02.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-110785
8564 8u https://doi.org/10.4137/IJTR.S16800
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:225288889

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy